# Darlene Deptula-Hicks 是一位擁有超過30年公私營生命科學公司經驗的資深生物技術高管，曾擔任高階主管、財務長及董事會職務。

*biotech · news · 2026-06-10 · Business Wire*

## Key points

- Darlene Deptula-Hicks 已加入 Aldeyra Therapeutics 董事會。
- Deptula-Hicks 目前擔任臨床階段腫瘤生技公司 Normunity 的代理財務長。
- Aldeyra 的產品線包括針對乾眼症及原發性玻璃體視網膜淋巴瘤的後期候選藥物。
- Aldeyra 的藥物目標為 RASP 調節，旨在優化多重途徑並降低毒性。

LEXINGTON, Mass.--(BUSINESS WIRE)--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced the appointment of Darlene Deptula-Hicks to Aldeyra’s board of directors (the Board). “Ms. Deptula-Hicks brings decades of experience working with both publicly traded and venture-backed biotechnology companies,” stated Richard H. Douglas, Ph.D., Chairman of the Board. “We look forward to leveraging her expertise as Aldeyra continues to progress towards potential commercialization of therapies that address an unmet medical need.” Ms. Deptula-Hicks is a senior biotechnology executive with over 30 years of experience across public and private life science companies, spanning therapeutics, diagnostics, medical devices, and emerging healthcare technologies. She has held senior executive, chief financial officer, board roles, and has extensive experience supporting companies through initial public offerings, major capital raises, strategic partnerships, and M&A transactions. Ms. Deptula-Hicks currently serves as the acting Chief Financial Officer of Normunity Inc., a clinical-stage biotech company focused on novel therapies to treat cancer. Previously, she served as Chief Financial Officer of F-star Therapeutics, Inc. Ms. Deptula-Hicks holds an M.B.A. from Rivier University and a B.S. in Accounting from Southern New Hampshire University. “I look forward to supporting Aldeyra’ s Board and partnering with the leadership team to drive sustainable long-term growth,” Ms. Deptula-Hicks stated. About Aldeyra Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-248, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.

**Companies:** Aldeyra Therapeutics, Inc., Normunity Inc., F-star Therapeutics, Inc.
**Countries:** United States

[Read the full story on Business Wire](https://www.businesswire.com/news/home/20260609197950/en/Aldeyra-Therapeutics-Appoints-Darlene-Deptula-Hicks-to-Board-of-Directors)

---

Canonical: https://newsio.io/zh-TW/n/f4d4475e-ccc5-4859-a831-572febcd8081/darlene-deptula-hicks-30
Summarized by Newsio from Business Wire. https://newsio.io/how-it-works